Alnylam Pharmaceuticals’ (ALNY) “Buy” Rating Reaffirmed at HC Wainwright

Alnylam Pharmaceuticals (NASDAQ:ALNY)‘s stock had its “buy” rating reiterated by equities research analysts at HC Wainwright in a research note issued on Wednesday,Benzinga reports. They currently have a $500.00 price objective on the biopharmaceutical company’s stock. HC Wainwright’s price target would indicate a potential upside of 91.18% from the stock’s previous close.

ALNY has been the topic of a number of other reports. Sanford C. Bernstein decreased their target price on shares of Alnylam Pharmaceuticals from $314.00 to $310.00 and set an “outperform” rating on the stock in a research note on Tuesday, January 7th. Wells Fargo & Company boosted their price target on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an “equal weight” rating in a research note on Friday, March 21st. Stifel Nicolaus boosted their target price on Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the stock a “buy” rating in a research note on Monday. JPMorgan Chase & Co. raised Alnylam Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their price objective for the stock from $280.00 to $328.00 in a research report on Monday, March 24th. Finally, Bank of America boosted their target price on shares of Alnylam Pharmaceuticals from $302.00 to $325.00 and gave the stock a “buy” rating in a research note on Friday, March 21st. One research analyst has rated the stock with a sell rating, five have given a hold rating and twenty-one have given a buy rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $316.25.

Alnylam Pharmaceuticals Price Performance

NASDAQ ALNY traded up $5.78 during trading hours on Wednesday, reaching $261.54. The company’s stock had a trading volume of 322,397 shares, compared to its average volume of 830,846. The company has a debt-to-equity ratio of 15.27, a current ratio of 2.78 and a quick ratio of 2.71. Alnylam Pharmaceuticals has a 1-year low of $141.98 and a 1-year high of $304.39. The company’s 50-day moving average is $260.15 and its two-hundred day moving average is $260.51. The firm has a market capitalization of $34.02 billion, a price-to-earnings ratio of -120.61 and a beta of 0.39.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings results on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). On average, equities analysts predict that Alnylam Pharmaceuticals will post -1.7 EPS for the current year.

Insider Buying and Selling

In other news, Director Phillip A. Sharp sold 11,250 shares of the firm’s stock in a transaction on Thursday, January 23rd. The stock was sold at an average price of $275.00, for a total value of $3,093,750.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, CMO Pushkal Garg sold 52,592 shares of the business’s stock in a transaction dated Monday, January 27th. The stock was sold at an average price of $285.00, for a total transaction of $14,988,720.00. Following the completion of the sale, the chief marketing officer now owns 11,989 shares in the company, valued at $3,416,865. This represents a 81.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 71,234 shares of company stock valued at $19,958,097. Corporate insiders own 1.50% of the company’s stock.

Institutional Trading of Alnylam Pharmaceuticals

Several institutional investors and hedge funds have recently modified their holdings of the business. Larson Financial Group LLC raised its position in shares of Alnylam Pharmaceuticals by 187.2% during the 4th quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 73 shares during the last quarter. Park Square Financial Group LLC acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $28,000. R Squared Ltd acquired a new stake in shares of Alnylam Pharmaceuticals during the fourth quarter valued at $33,000. Colonial Trust Co SC acquired a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Finally, OFI Invest Asset Management purchased a new position in Alnylam Pharmaceuticals in the 4th quarter valued at about $35,000. Hedge funds and other institutional investors own 92.97% of the company’s stock.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.